Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?
American Medical Association fact sheet on ocrelizumab
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Mycophenolate mofetil in multiple sclerosis.
Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
Experimental autoimmune encephalomyelitis in the mouse.
Mouse models for multiple sclerosis: historical facts and future implications.
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial.
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
CellCept (Product Insert)
Harry Lee Parker and paroxysmal dysarthria and ataxia.
CellCept Drug Details
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Precision medicine in chronic disease management: The MS BioScreen.
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
Rapidly progressive cerebellar ataxia in West Wales.

Pages